Comparative efficacy between glimepiride and metformin in preventing progression of prediabetes to type 2 diabetes

Udaya M. Kabadi

University of Iowa, Iowa City, USA.

DOI: 10.4236/jdm.2013.33019                

Abstract

Background: Several recent studies have shown that treatment with therapeutic lifestyle changes, and/or several drugs retard progression of prediabetes to type 2 diabetes. However, none of these studies used a Sulfonylurea (SU), although in UKPDS, SUs delayed the progression of hyperglycemia and several subjects would have been categorized as having prediabetes by present diagnostic criteria. Thus, SUs may have delayed the progression in this group as well. Objective: Therefore, we examined comparative efficacy of glimepiride and metformin in progression to diabetes in subjects with prediabetes. Methods: Twenty men and 18 women ages 28 - 81 years with prediabetes were followed for 5 - 9 years. Prediabetes was diagnosed by impaired fasting glucose and HbA1Cbetween 5.7% - 6.4% with two consecutive determinations as recommended by American Diabetes Association. Twenty obese subjects were administered metformin 500 mg/day and 18 non obese subjects received glimepiride 0.5 mg/day, in addition to dietary and exercise counseling. Results: Mean duration of follow up was 5.8 ± 0.2 years. Fasting Plasma Glucose (FPG) and HbA1Cdeclined to <100 mg/dl and <5.7% in all subjects by 6 months. During the follow up period, 9 of 20 (45%) subjects receiving metformin and 5 of 18 (27%) in glimepiride group progressed to diabetes (p < 0.01) as determined by FPG ≥ 126 mg/dl and HbA1C≥ 6.5% (RR, 1.61 with Confidence Interval, 1.43 - 1.74 for metformin vs glimepiride; p < 0.01). The mean duration to progression was 32 ± 4 months in metformin group and 47 ± 5 months in subjects receiving glimepiride. FPG and HbA1clevels promptly returned to <100 mg/dl and <5.7% on increasing daily dose of both metformin (1000 - 1500 mg) and glimepiride (2 - 4 mg). The glycemic control was maintained till the end of observation period. None of the subjects in either group manifested a cardiovascular event nor any of the subjects died during the period of observation. Conclusion: Glimepiride may be more effective in delaying the progression of prediabetes to diabetes in non-obese subjects in comparison to metformin in obese subjects with no significant difference in cardiovascular morbidity or overall mortality.

Keywords

Type 2 Diabetes Pharmacotherapy; CVD/Lipids/Insulin Resistance; Prediabetes

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Eriksson, K.F. and Lindgarde, F, (1991) Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malm? feasibility study. Diabetologia, 34, 891-898. doi:10.1007/BF00400196
[2]	Pan, X.R., Li, G.W., Hu, Y.H., et al. (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and diabetes study. Diabetes Care, 20, 537-544. doi:10.2337/diacare.20.4.537
[3]	Tuomilehto, J., Lindstr?m, J., Eriksson, J.G., et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. The New England Journal of Medicine, 344, 1343-1350. doi:10.1056/NEJM200105033441801
[4]	Knowler, W.C., Barrett-Connor, E., Fowler, S.E., et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England Journal of Medicine, 346, 393-403. doi:10.1056/NEJMoa012512
[5]	Ramachandran, A., Snehalatha, C., Mary, S., et al. 2006 The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia, 49, 289-297. doi:10.1007/s00125-005-0097-z
[6]	Perreault, L., Kahn, S.E., Christophi, C.A., et al. (2009) Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program. Diabetes Care, 32, 1583-1588. doi:10.2337/dc09-0523
[7]	Saaristo, T., Moilanen, L., Korpi-Hy?v?lti, E., et al. (2010) Lifestyle intervention for prevention of type 2 diabetes in primary health care: One-year follow-up of the Finnish National Diabetes Prevention Program (FIN-D2D). Diabetes Care, 33, 2146-2151. doi:10.2337/dc10-0410
[8]	Perreault, L., Pan, Q., Mather, K.J., et al. (2012) Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: Results from the Diabetes Prevention Program Outcomes Study. Lancet, 379, 2243-2251. doi:10.1016/S0140-6736(12)60525-X
[9]	American Diabetes Association (2012) Standards of medical care in diabetes—2012. Diabetes Care, 35, S11-S63. doi:10.2337/dc12-s011
[10]	Chiasson, J.L., Josse, R.G., Gomis, R., et al. (2002) Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet, 359, 2072-2077.
[11]	Kawamori, R., Tajima, N., Iwamoto, Y., et al. (2009) Voglibose for prevention of type 2 diabetes mellitus: A randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet, 373, 1607-1614. doi:10.1016/S0140-6736(09)60222-1
[12]	DREAM (Diabetes REduction Assessment with Ramipril and Rosiglitazone Medication) Trial Investigators, Gerstein, H.C., Yusuf, S., Bosch, J., et al. (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet, 368, 1096-1105. doi:10.1016/S0140-6736(06)69420-8
[13]	NAVIGATOR Study Group (2010) Effect of valsartan on the incidence of diabetes and cardiovascular events. The New England Journal of Medicine, 362, 1477-1490. doi:10.1056/NEJMoa1001121
[14]	Zinman, B., Harris, S.B., Neuman, J., et al. (2010) Lowdose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): A double-blind randomised controlled study. Lancet, 376, 103-111. doi:10.1016/S0140-6736(10)60746-5
[15]	DeFronzo, R.A., Tripathy, D., Schwenke, D.C., et al. (2011) Pioglitazone for diabetes prevention in impaired glucose tolerance. The New England Journal of Medicine, 364, 1104-1115. doi:10.1056/NEJMoa1010949
[16]	Faghihimani, E., Aminorroaya, A., Rezvanian, H., et al. (2012) Salsalate reduces insulin resistance and plasma glucose level in persons with prediabetes. Endocrine Practice, 11, 1-17.
[17]	UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352, 837-853. doi:10.1016/S0140-6736(98)07019-6
[18]	UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 352, 854-865. doi:10.1016/S0140-6736(98)07037-8
[19]	Colagiuri, S., Cull, C.A., Holman, R.R., et al. (2002) Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes? UK prospective diabetes study 61. Diabetes Care, 25, 1410-1417. doi:10.2337/diacare.25.8.1410
[20]	Kabadi, U.M. (2002) United Kingdom prospective diabetes study: A different perspective. Endocrine Practice, 8, 61-64. doi:10.4158/EP.8.1.61
[21]	Karunakaran, S., Hammersley, M.S., Morris, R.J., et al. (1997) The Fasting Hyperglycaemia Study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose. Metabolism, 46, 56-60. doi:10.1016/S0026-0495(97)90319-X
[22]	Sartor, G., Scherstén, B., Carlstr?m, S., et al.(1980) Tenyear follow-up of subjects with impaired glucose tolerance: Prevention of diabetes by tolbutamide and diet regulation. Diabetes, 29, 41-49. doi:10.2337/diabetes.29.1.41
[23]	Lindblad, U., Lindberg, G., M?nsson, N.O., et al. (2011) Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes studY (NANSY). Diabetes, Obesity and Metabolism, 13, 185-188. doi:10.1111/j.1463-1326.2010.01331.x
[24]	Alvarsson, M., Wajngot, A., Cerasi, E., et al. (2005) K-value and low insulin secretion in a non-obese white population: Predicted glucose tolerance after 25 years. Diabetologia, 48, 2262-2268. doi:10.1007/s00125-005-1929-6
[25]	Sonnenberg, G.E., Garg, D.C., Weidler, D.J., et al. (1997) Short-term comparison of onceversus twice-daily administration of glimepiride in patients with non-insulindependent diabetes mellitus. The Annals of Pharmacotherapy, 31, 671-676.
[26]	Korytkowski, M., Thomas, A., Reid, L., et al. (2002) Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care, 25, 1607-1611. doi:10.2337/diacare.25.9.1607
[27]	Singh, J., Unnikrishnan, A.G., Agrawal, N.K., et al. (2002) Immunoreactive insulin response to a single dose of glimepiride in lean type 2 diabetic subjects. Journal of the Association of Physicians of India, 50, 1232-1235.
[28]	Kabadi, M.U. and Kabadi, U.M. (2004) Effects of glimepiride on insulin secretion and sensitivity in patients with recently diagnosed type 2 diabetes mellitus. Clinical Therapeutics, 26, 63-69. doi:10.1016/S0149-2918(04)90006-9
[29]	Bruce, D.G., Chisholm, D.J., Storlien, L.H., et al. (1988) Physiological importance of deficiency in early prandial insulin secretion in non-insulin dependent diabetes. Diabetes, 37, 736-744. doi:10.2337/diabetes.37.6.736
[30]	Mitrakou, A., Kelley. D., Mokan, M., et al. (1992) Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. The New England Journal of Medicine, 326, 22-29. doi:10.1056/NEJM199201023260104
[31]	Van Haeften, T.W., Pimenta, W., Mitrakou, A., et al. (2000) Relative contributions of beta-cell function and tissue insulin sensitivity to fasting and postglucose-load glycemia. Metabolism, 49, 1318-1325. doi:10.1053/meta.2000.9526
[32]	UK Prospective Diabetes Study Group (1995) UK prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: A progressive disease. Diabetes, 44, 1249-1258. Erratum in: Diabetes, 45, 1655. doi:10.2337/diabetes.44.11.1249
[33]	Pratley, R.E. and Weyer, C. (2001) The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia, 44, 929-945. doi:10.1007/s001250100580
[34]	Kabadi, U.M. and Kabadi, M.U. (2011) Early postprandial Insulin secretion: Its relation to Insulin sensitivity, Journal of Diabetes Mellitus, 1, 1-5. doi:10.4236/jdm.2011.11001
[35]	DeFronzo, R.A. and Abdul-Ghani, M.A. (2011) Preservation of beta-cell function: The key to diabetes prevention. The Journal of Clinical Endocrinology & Metabolism, 96, 2354-2366. doi:10.1210/jc.2011-0246
[36]	Müller, G., Satoh, Y. and Geisen, K. (1995) Extrapancreatic effects of sulfonylureas—A comparison between glimepiride and conventional sulfonylureas. Diabetes Research and Clinical Practice, 28, S115-S137. doi:10.1016/0168-8227(95)01089-V
[37]	Müller, G. and Geisen, K. (1996) Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at adipocytes. Hormone and Metabolic Research, 28, 469-487. doi:10.1055/s-2007-979839
[38]	Eckel, J. (1996) Direct effects of glimepiride on protein expression of cardiac glucose transporters. Hormone and Metabolic Research, 28, 508-511. doi:10.1055/s-2007-979842
[39]	Kabadi, M.U. and Kabadi, U.M. (2003) Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus. Annals of Pharmacotherapy, 37, 1572-1576. doi:10.1345/aph.1C492
[40]	Melander, A. (1996) Review of previous impaired glucose tolerance intervention studies. Diabetic Medicine, 13, S20-S22.
[41]	Melander, A. (1998) Pharmacological intervention: The antidiabetic approach. European Journal of Clinical Investigation, 28, 23-25. doi:10.1046/j.1365-2362.1998.0280s2023.x
[42]	Faerch, K., Borch-Johnsen, K., Holst, J.J., et al. (2009) Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: Does it matter for prevention and treatment of type 2 diabetes? Diabetologia, 52, 1714-1723. doi:10.1007/s00125-009-1443-3
[43]	DREAM Trial Investigators (2011) Incidence of diabetes following ramipril or rosiglitazone withdrawal. Diabetes Care, 34, 1265-1269. doi:10.2337/dc10-1567
[44]	Armato, J., DeFronzo, R.A., Abdul-Ghani, M., et al. (2012) Successful treatment of prediabetes in clinical practice: Targeting insulin resistance and β-cell dysfunction. Endocrine Practice, 18, 342-350. doi:10.4158/EP11194.OR